Rollout of new tools to curb RSV expected to be smoother this year

Last updated: October 5, 2024 11:40 am

For Beyfortus, the timing is also crucial. The injection has to be given to infants before their first RSV season, ideally at birth or within a few days of leaving the hospital. For some high-risk babies, the shot may need to be repeated before their second RSV season. This means coordinating with birthing hospitals, pediatricians, and pharmacies to ensure that all eligible babies receive the protection they need in a timely manner.

Despite the challenges, the introduction of these new tools represents a major step forward in the fight against RSV. The hope is that by significantly reducing the number of severe RSV cases in young children, hospitals will be better equipped to handle other medical emergencies and resources can be allocated more efficiently.

Georgina Peacock and her colleagues are optimistic about the impact these vaccines and antibodies will have on the health of infants across the country. The memories of that night when she admitted 20 babies struggling to breathe due to RSV are still fresh in her mind, serving as a constant reminder of the importance of this work.

As the rollout of these new medical tools continues, the focus remains on improving access, education, and coordination to ensure that every eligible baby receives the protection they need against RSV. The dedication and perseverance of those involved in this effort are a testament to their commitment to improving the health and well-being of the youngest members of our society.

With continued support and collaboration, the hope is that RSV season will no longer be a time of fear and uncertainty for families, but rather a season of prevention and protection for our most vulnerable population.

The next baby would need to be protected using the antibody injection known as Beyfortus. This injection provides protection against respiratory syncytial virus (RSV), a common virus that can cause serious illness in infants and young children. Babies born during or in the lead-up to RSV season, which runs from October to March, should receive Beyfortus at birth or before they leave the hospital. This ensures that they are protected during the peak RSV season.

Experts recommend that all infants born during RSV season receive the antibody injection to prevent exposure to RSV before they can receive the immunization from their pediatrician. This is crucial for protecting newborns from RSV, especially if there are older siblings at home who may be carriers of the virus.

For babies born in the off-season, the injection should be administered in early autumn as RSV season approaches. Pediatrician offices are the likely locations for these babies to receive the shot. It is essential to ensure that all newborns are protected from RSV, regardless of the season in which they are born.

The cost of the antibody injection is a significant concern for many families, as it is priced at $295 plus an administration fee for the maternal vaccine and nearly $520 for Beyfortus for babies going into their first RSV season. The high cost may pose challenges for uninsured families or those with limited financial resources. Efforts are being made to increase vaccination coverage among pregnant individuals to ensure the protection of both mother and baby.

Pharmacies have played a role in administering the maternal vaccine, but there have been instances of confusion leading to the wrong vaccine being given to pregnant individuals. Ensuring proper administration and storage of vaccines is crucial to prevent errors and ensure that the right vaccine is given to the right patient.

VFC-eligible babies are covered under the CDC’s Vaccines for Children program, which absorbs the cost of Beyfortus for uninsured and under-insured children. However, birthing hospitals need to be enrolled in the program to administer the vaccine. The CDC has seen an increase in the number of birthing hospitals enrolled in VFC, indicating a positive trend towards increasing access to vaccines for newborns.

Overall, the protection of newborns against RSV is a critical priority, and efforts are being made to ensure that all babies receive the necessary antibody injections for their health and well-being. Vaccination plays a crucial role in preventing the spread of infectious diseases and protecting vulnerable populations, such as infants and young children. The American Hospital Association (AHA) is working closely with its members and the Centers for Disease Control and Prevention (CDC) to streamline the process for birthing hospitals to access and administer Beyfortus, a new vaccine for preventing respiratory syncytial virus (RSV) in infants. This collaboration aims to make it easier for hospitals to obtain and distribute the vaccine to eligible infants.

Sanofi, the manufacturer of Beyfortus, has been receiving orders for the vaccine for several months. They are offering a 2% discount on doses ordered in July and August to birthing hospitals and pediatricians purchasing doses for the private market, rather than through the Vaccines for Children program. This discount incentivizes healthcare providers to stock up on doses of Beyfortus for their patients.

While there is a steady supply of Beyfortus expected throughout the season, there are concerns about equitable distribution. The Association of Immunization Managers is monitoring the situation closely to ensure that all hospitals have access to the vaccine. CDC officials acknowledge that it can take up to five years for a new vaccine like Beyfortus to be fully integrated into the healthcare system, but they are optimistic that the process will be expedited.

Dr. Domachowske from SUNY Upstate Medical University is hopeful that the benefits of Beyfortus in preventing RSV in infants will soon be evident. A recent CDC study showed that the vaccine was 90% effective in preventing RSV hospitalizations in infants from October 2023 to February 2024. Despite distribution challenges, healthcare providers are committed to increasing the number of eligible infants receiving the vaccine to protect them from RSV.

In conclusion, the collaboration between the AHA, CDC, and healthcare providers is essential in ensuring the successful distribution and administration of Beyfortus to prevent RSV in infants. With ongoing efforts to improve access and increase vaccination rates, the societal benefits of protecting babies from RSV will become more apparent.